Rukobia

Product manufactured by Viiv Healthcare Company

Application Nr Approved Date Route Status External Links
NDA212950 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Rukobia, In Combination With Other Antiretroviral(S), Is Indicated For The Treatment Of Human Immunodeficiency Virus Type 1 (Hiv-1) Infection In Heavily Treatment-Experienced Adults With Multidrug-Resistant Hiv-1 Infection Failing Their Current Antiretroviral Regimen Due To Resistance, Intolerance, Or Safety Considerations [See Clinical Studies ( 14 )]. Rukobia, A Human Immunodeficiency Virus Type 1 (Hiv-1) Gp120-Directed Attachment Inhibitor, In Combination With Other Antiretroviral(S), Is Indicated For The Treatment Of Hiv-1 Infection In Heavily Treatment-Experienced Adults With Multidrug-Resistant Hiv-1 Infection Failing Their Current Antiretroviral Regimen Due To Resistance, Intolerance, Or Safety Considerations. ( 1 , 12.4 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Fostemsavir Tromethamine FOSTEMSAVIR TROMETHAMINE ZINC14210883

Comments